Tag: Duchenne muscular dystrophy

Sarepta Therapeutics stock in strong uptrend.

Sarepta Therapeutics In Strong Uptrend From Exondys 51


Sarepta Therapeutics could get European marketing approval for Exondys 51 at any time which will boost sales. Meanwhile, the company has great growth and is advancing other drugs through its pipeline.